To include your compound in the COVID-19 Resource Center, submit it here.

IMA901: Additional Phase II data

Additional data from the open-label, exploratory, European Phase II IMA901-202 trial in 61 evaluable patients with advanced or metastatic RCC who had failed previous first-line therapy showed that

Read the full 286 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE